Ionis shareholder plans sale of 6,988 shares

A shareholder of Ionis Pharmaceuticals has filed a notice to sell 6,988 shares of common stock through Morgan Stanley Smith Barney on 01/30/2026 on NASDAQ.

Accepted by SEC EDGAR 01/30/2026 - 08:34 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

A shareholder of Ionis Pharmaceuticals has filed a notice to sell 6,988 shares of common stock through Morgan Stanley Smith Barney on 01/30/2026 on NASDAQ. The filing lists an aggregate market value of $580,049.03 for this planned sale.

The shares were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan and treated as compensation. Over the prior three months, the same account sold 12,922 common shares for $971,992.84.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Ionis Pharmaceuticals (IONS) shares are planned for sale in this Form 144?

The notice covers a planned sale of 6,988 shares of Ionis Pharmaceuticals common stock. These shares are to be sold through Morgan Stanley Smith Barney on NASDAQ, with the filing listing an aggregate market value of $580,049.03 for the transaction.

What is the aggregate market value of the Ionis (IONS) shares to be sold?

The planned sale has an aggregate market value of $580,049.03. This value relates to the 6,988 common shares of Ionis Pharmaceuticals listed in the Form 144, to be sold through Morgan Stanley Smith Barney on the NASDAQ market.

When were the Ionis Pharmaceuticals (IONS) shares acquired and how?

The shares were acquired on 01/29/2026 as performance stock units granted under Ionis Pharmaceuticals’ 2011 Equity Incentive Plan. The filing describes the nature of payment as compensation, indicating the seller received these shares as part of an equity award.

What prior Ionis (IONS) share sales are disclosed in the last three months?

The filing reports a previous sale of 12,922 shares of Ionis Pharmaceuticals common stock on 01/16/2026. Those shares were sold through Morgan Stanley Smith Barney, generating $971,992.84 in gross proceeds for the account referenced in the notice.

On which exchange will the Ionis Pharmaceuticals (IONS) shares in this Form 144 be sold?

The Form 144 states that the 6,988 common shares of Ionis Pharmaceuticals are expected to be sold on the NASDAQ exchange. Morgan Stanley Smith Barney, based at 1585 Broadway in New York, is listed as the broker handling the transaction.

Who is the broker for the planned Ionis (IONS) stock sale disclosed in the Form 144?

The broker listed is Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036. This firm is designated to handle the sale of 6,988 Ionis Pharmaceuticals common shares on NASDAQ as described in the Form 144 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001074773
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	HOUGEN ELIZABETH L
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	6988	580049.03	161137930	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			6988	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/16/2026	12922	971992.84

144: Remarks and Signature

Remarks
Date of Notice	01/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Elizabeth L. Hougen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)